| Literature DB >> 26150706 |
Xiao Lin1, Dan Xiong1, Yi-Qun Peng1, Zhi-Feng Sheng1, Xi-Yu Wu1, Xian-Ping Wu1, Feng Wu2, Ling-Qing Yuan1, Er-Yuan Liao1.
Abstract
With the progressive aging of the population, osteoporosis has gradually grown into a global health problem for men and women aged 50 years and older because of its consequences in terms of disabilities and fragility fractures. This is especially true in the People's Republic of China, which has the largest population and an increasing proportion of elderly people, as osteoporosis has become a serious challenge to the Chinese government, society, and family. Apart from the fact that all osteoporotic fractures can increase the patient's morbidity, they can also result in fractures of the hip and vertebrae, which are associated with a significantly higher mortality. The cost of osteoporotic fractures, moreover, is a heavy burden on families, society, and even the country, which is likely to increase in the future due, in part, to the improvement in average life expectancy. Therefore, understanding the epidemiology of osteoporosis is essential and is significant for developing strategies to help reduce this problem. In this review, we will summarize the epidemiology of osteoporosis in the People's Republic of China, including the epidemiology of osteoporotic fractures, focusing on preventive methods and the management of osteoporosis, which consist of basic measures and pharmacological treatments.Entities:
Keywords: epidemiology; fracture; management; osteoporosis
Mesh:
Substances:
Year: 2015 PMID: 26150706 PMCID: PMC4485798 DOI: 10.2147/CIA.S54613
Source DB: PubMed Journal: Clin Interv Aging ISSN: 1176-9092 Impact factor: 4.458
World Health Organization criteria for the diagnosis of osteoporosis
| Diagnosis categories | Definitions |
|---|---|
| Normal | BMD within 1 SD of the young adult mean value (T-score ≥ −1.0) |
| Osteopenia | BMD >1 SD below the young adult mean, but <2.5 SD below this value (−2.5 < T-score < −1.0) |
| Osteoporosis | BMD ≥2.5 SD below the young adult mean value (T-score ≤ −2.5) |
| Severe (established) osteoporosis | BMD ≥2.5 SD below the young adult mean value (T-score ≤ −2.5) and in the presence of ≥1 fragility fractures |
Note: Data from World Health Organization Study Group,10 and Kanis et al.14
Abbreviations: BMD, bone mineral density; SD, standard deviation.
Risk factors for osteoporosis
| Categories | Risk factors |
|---|---|
| General factors | Female |
| Age | |
| Height | |
| Body mass index | |
| History of fragility fracture | |
| Body composition | Fat mass |
| Lean mass | |
| Dietary factors | Vitamin D |
| Calcium | |
| Lifestyle | Sedentary or lack of exercise |
| Cigarette smoking | |
| Alcohol drinking | |
| Caffeine | |
| Genetic factors | |
| A family history of fracture | |
| Medications | Glucocorticoids |
| Immunosuppressants | |
| Heparin | |
| Anticonvulsants | |
| Thiazolidenediones | |
| Proton pump inhibitors | |
| Diseases | Endocrine disorders |
| Gastrointestinal diseases | |
| Hematologic diseases | |
| Other disorders |
Medications for the prevention/treatment of OP
| Categories | Agents | Indications | Dosage and method | Effects on BMD | Effects on risk of fractures | Side effects | Prevention or treatment |
|---|---|---|---|---|---|---|---|
| Antiabsorptive | Alendronate | PMOP, men’s OP, and GIOP | Oral 10 mg/day, 70 mg/week | ↑Lumbar spine and hip | ↓Vertebral, nonvertebral, and hip | Bone, joint or muscle pain, inflammation of the eye, dyspepsia, esophagitis, and osteonecrosis of the jaw | Prevention and treatment |
| Zoledronic acid | PMOP | IV 5 mg/year, | |||||
| Ibandronate | PMOP | IV 3 mg/3 months | ↓Vertebral | ||||
| Calcitonin | PMOP | Nasal 200 IU/day or IM 50 IU/day | ↑Spine | ↓Vertebral, nonvertebral | Facial or hand flushing, rash, nausea, urinary frequency, rhinitis, epistaxis, headache, and back or joint pain | Treatment, but not prevention | |
| HRT | PMOP | Individualized dose | ↑Spine and hip | ↓Vertebral, nonvertebral | Increasing fracture risk, cardiovascular, uterine cancer, breast cancer, stroke, and thromboembolic event risk | Prevention and treatment | |
| SERMs | PMOP | 60 mg/day | ↑Spine and femoral neck | ↓Vertebral | Hot flushes, leg cramps, swelling, a flu-like syndrome, peripheral edema and vasomotor symptoms, and deep vein thrombosis | Prevention and treatment | |
| Denosumab | PMOP | Subcutaneous injection 60 mg/6 months | ↑Lumbar spine and hip | ↓Vertebral, nonvertebral, and hip | Hypocalcemia, skin infections, osteonecrosis of the jaw, and atypical femoral fractures | Treatment | |
| Anabolic | PTH and teriparatide | PMOP and men’s OP | Subcutaneous injection 20 μg/day, less than 2 years | ↑Spine and hip | ↓Vertebral, nonvertebral | Leg cramps, vertigo, pain, nausea, orthostatic hypotension, and a modest rise in serum and urine calcium | Treatment |
| Combined Antiresorption with stimulated bone formation | Strontium ranelate | PMOP | Oral 2 g/day | ↑Lumbar spine, femoral neck, and total hip | ↓Vertebral, nonvertebral | Headache, nausea, diarrhea and skin reaction syndrome, Stevens–Johnson syndrome, and toxic epidermal necrolysis | Prevention |
Abbreviations: OP, osteoporosis; BMD, bone mineral density; PMOP, postmenopausal osteoporosis; GIOP, glucocorticoid-induced osteoporosis; IV, intravenous; IM, intramuscular; HRT, hormone replacement therapy; SERMs, selective estrogen receptor modulators; PTH, parathyroid hormone.